The fiercely competitive nature of the oncology industry makes the companies invest heavily in research and development to bring in top cancer-treating drug patents. Consequently, the expiration of patents for cancer drugs creates significant opportunities for companies specializing in generic medications.
Identifying these patents can help enterprises expand and diversify their generic drug portfolios. This strategic move reduces dependence on a single drug or product and proactively mitigates risk by diversifying drug portfolios.
Furthermore, this comprehensive list offers crucial insights such as the active ingredient, applicant, and route – vital information for generic drug manufacturers aiming to enter the cancer treatment market strategically. For instance, the route detail guides formulation strategies, ensuring that generic versions align with the original drug’s delivery method for therapeutic equivalence.
Access the Full Report:
While this article highlights key details, you can obtain the complete PDF version of “Cancer Drug Patents Expiring in 2024-2028” by simply filling out the form below. Don’t miss this opportunity to stay ahead in the dynamic pharmaceutical landscape.
Abraxane
Paclitaxel
Applicant:
Bristol-Myers Squibb Co
| Patents | Expiration Date |
| US7758891 | 2026-02-21 |
| US7820788 | 2024-10-27 |
| US8034375 | 2026-08-13 |
| US8268348 | 2026-02-21 |
| US9101543 | 2026-02-21 |
Ingredients: Paclitaxel
Route: Powder; Intravenous
Akeega
Abiraterone Acetate; Niraparib Tosylate
Applicant:
Janssen Biotech Inc
| Patents | Expiration Date |
| US8071579 | 2027-08-12 |
| US8143241 | 2027-08-12 |
Ingredients: Abiraterone Acetate; Niraparib Tosylate
Route: Tablet; Oral
Beleodaq
Belinostat
Applicant:
Acrotech Biopharma Inc
| Patents | Expiration Date |
| US6888027 | 2026-08-10 |
Ingredients: Belinostat
Route: Powder; Intravenous
Belrapzo
Bendamustine Hydrochloride
Applicant:
Eagle Pharmaceuticals Inc
| Patents | Expiration Date |
| US8791270 | 2026-01-12 |
Ingredients: Bendamustine Hydrochloride
Route: Solution; Intravenous
Bendeka
Bendamustine Hydrochloride
Applicant:
Eagle Pharmaceuticals Inc
| Patents | Expiration Date |
| US8791270 | 2026-01-12 |
Ingredients: Bendamustine Hydrochloride
Route: Solution; IV (Infusion)
Erivedge
Vismodegib
Applicant:
Genentech Inc
| Patents | Expiration Date |
| US9278961 | 2028-12-15 |
Ingredients: Vismodegib
Route: Capsule; Oral
Erleada
Apalutamide
Applicant:
Janssen Biotech Inc
| Patents | Expiration Date |
| US8802689 | 2027-03-27 |
Ingredients: Apalutamide
Route: Tablet; Oral
Folotyn
Pralatrexate
Applicant:
Acrotech Biopharma Inc
| Patents | Expiration Date |
| US7622470 | 2025-05-31 |
Ingredients: Pralatrexate
Route: Solution; Intravenous
Gilotrif
Afatinib Dimaleate
Applicant:
Boehringer Ingelheim
| Patents | Expiration Date |
| US9539258 | 2026-11-09 |
Ingredients: Afatinib Dimaleate
Route: Tablet; Oral
Imbruvica
Ibrutinib
Applicant:
Pharmacyclics LLC
| Patents | Expiration Date |
| US8476284 | 2026-12-28 |
| US8476284 | 2026-12-28 |
| US8476284 | 2026-12-28 |
| US8497277 | 2026-12-28 |
| US8563563 | 2027-04-26 |
| US8952015 | 2026-12-28 |
| US8952015 | 2026-12-28 |
| US8952015 | 2026-12-28 |
| US8952015 | 2026-12-28 |
| US8952015 | 2026-12-28 |
Ingredients: Ibrutinib
Route: Capsule and Tablet; Oral
Ixempra Kit
Ixabepilone
Applicant:
R-Pharm US LLC
| Patents | Expiration Date |
| US7312237 | 2024-08-21 |
Ingredients: Ixabepilone
Route: Injectable; Intravenous
Lazanda
Fentanyl Citrate
Applicant:
BTCP Pharma Llc
| Patents | Expiration Date |
| US8216604 | 2024-10-03 |
| US8889176 | 2024-01-16 |
Ingredients: Fentanyl Citrate
Route: Spray, Metered; Nasal
Lenvima
Lenvatinib Mesylate
Applicant:
Eisai Inc
| Patents | Expiration Date |
| US9006256 | 2027-07-27 |
Ingredients: Lenvatinib Mesylate
Route: Capsule; Oral
Locametz
Gallium Ga-68 Gozetotide
Applicant:
Novartis Pharmaceuticals Corp
| Patents | Expiration Date |
| US11369590 | 2028-08-15 |
Ingredients: Gallium Ga-68 Gozetotide
Route: Powder; Intravenous
Lonsurf
Tipiracil Hydrochloride; Trifluridine
Applicant:
Taiho Oncology Inc
| Patents | Expiration Date |
| US7799783 | 2026-12-16 |
Ingredients: Tipiracil Hydrochloride; Trifluridine
Route: Tablet; Oral
Lynparza
Olaparib
Applicant:
Astrazeneca Pharmaceuticals LP
| Patents | Expiration Date |
| US8071579 | 2027-08-12 |
| US8071579 | 2027-08-12 |
| US8143241 | 2027-08-12 |
| US8143241 | 2027-08-12 |
| US8912187 | 2024-03-12 |
| US8912187 | 2024-03-12 |
| US8912187 | 2024-03-12 |
| US9169235 | 2024-03-12 |
| US9169235 | 2024-03-12 |
Ingredients: Olaparib
Route: Tablet; Oral and Capsule; Oral
Mekinist
Trametinib Dimethyl Sulfoxide
Applicant:
Novartis Pharmaceuticals Corp
| Patents | Expiration Date |
| US8835443 | 2025-06-10 |
Ingredients: Trametinib Dimethyl Sulfoxide
Route: Tablet; Oral
Nerlynx
Neratinib Maleate
Applicant:
Puma Biotechnology Inc
| Patents | Expiration Date |
| US10035788 | 2028-10-15 |
| US7982043 | 2025-10-08 |
| US9139558 | 2028-10-15 |
| US9630946 | 2028-10-15 |
Ingredients: Neratinib Maleate
Route: Tablet; Oral
Onivyde
Irinotecan Hydrochloride
Applicant:
Ipsen Biopharmaceuticals Inc
| Patents | Expiration Date |
| US8703181 | 2025-05-02 |
Ingredients: Irinotecan Hydrochloride
Route: Injectable, Liposomal; Intravenous
Onsolis
Fentanyl Citrate
Applicant:
Adalvo Ltd
| Patents | Expiration Date |
| US9579288 | 2027-07-23 |
| US9597288 | 2027-07-23 |
Ingredients: Fentanyl Citrate
Route: Film; Buccal
Orgovyx
Relugolix
Applicant:
Sumitomo Pharma Switzerland Gmbh
| Patents | Expiration Date |
| US8735401 | 2024-02-04 |
Ingredients: Relugolix
Route: Tablet; Oral
Orserdu
Elacestrant Dihydrochloride
Applicant:
Stemline Therapeutics Inc
| Patents | Expiration Date |
| US7612114 | 2026-08-18 |
| US8399520 | 2024-12-25 |
Ingredients: Elacestrant Dihydrochloride
Route: Tablet; Oral
Pluvicto
Lutetium Lu-177 Vipivotide Tetraxetan
Applicant:
Novartis Pharmaceuticals Corp
| Patents | Expiration Date |
| US10406240 | 2028-08-15 |
| US11318121 | 2028-08-15 |
Ingredients: Lutetium Lu-177 Vipivotide Tetraxetan
Route: Solution; Intravenous
Revlimid
Lenalidomide
Applicant:
Bristol Myers Squibb
| Patents | Expiration Date |
| US8741929 | 2028-03-08 |
Ingredients: Lenalidomide
Route: Capsule; Oral
Rozlytrek
Entrectinib
Applicant:
Genentech Inc
| Patents | Expiration Date |
| US8673893 | 2028-07-08 |
| US9255087 | 2028-07-08 |
Ingredients: Entrectinib
Route: Capsule; Oral
Rubraca
Rucaparib Camsylate
Applicant:
Zr Pharma And Gmbh
| Patents | Expiration Date |
| US7351701 | 2024-07-23 |
| US7531530 | 2024-07-23 |
| US8071579 | 2027-08-12 |
| US8143241 | 2027-08-12 |
Ingredients: Rucaparib Camsylate
Route: Tablet; Oral
Tepmetko
Tepotinib Hydrochloride
Applicant:
EMD Serono Inc
| Patents | Expiration Date |
| US8658643 | 2028-07-04 |
| US8927540 | 2028-07-21 |
| US9403799 | 2028-07-04 |
Ingredients: Tepotinib Hydrochloride
Route: Tablet; Oral
Treanda
Bendamustine Hydrochloride
Applicant:
Cephalon Inc
| Patents | Expiration Date |
| US8791270 | 2026-01-12 |
| US8791270 | 2026-01-12 |
Ingredients: Bendamustine Hydrochloride
Route: Powder; Iv (Infusion)
Tukysa
Tucatinib
Applicant:
Seagen Inc
| Patents | Expiration Date |
| US7452895 | 2024-11-16 |
| US9693989 | 2027-05-09 |
Ingredients: Tucatinib
Route: Tablet; Oral
Valchlor
Mechlorethamine Hydrochloride
Applicant:
Helsinn Birex Pharmaceuticals Ltd
| Patents | Expiration Date |
| US8501819 | 2026-03-07 |
Ingredients: Mechlorethamine Hydrochloride
Route: Gel;Topical
Varubi
Rolapitant Hydrochloride
Applicant:
Tersera Therapeutics LLC
| Patents | Expiration Date |
| US7049320 | 2028-08-19 |
| US7049320 | 2028-08-19 |
| US7981905 | 2027-04-04 |
| US7981905 | 2027-04-04 |
| US8404702 | 2027-04-04 |
| US8404702 | 2027-04-04 |
Ingredients: Rolapitant Hydrochloride
Route: Emulsion; Intravenous and Tablet; Oral
Vizimpro
Dacomitinib
Applicant:
Pfizer Inc
| Patents | Expiration Date |
| US8623883 | 2025-05-05 |
Ingredients: Dacomitinib
Route: Tablet; Oral
Xalkori
Crizotinib
Applicant:
PF Prism CV
| Patents | Expiration Date |
| US7825137 | 2027-05-12 |
| US7825137 | 2027-05-12 |
Ingredients: Crizotinib
Route: Capsule and Capsule, Pellets; Oral
Xtandi
Enzalutamide
Applicant:
Astellas Pharma US Inc
| Patents | Expiration Date |
| US8183274 | 2026-08-24 |
| US8183274 | 2026-08-24 |
| US8183274 | 2026-08-24 |
| US9126941 | 2026-05-15 |
| US9126941 | 2026-05-15 |
Ingredients: Enzalutamide
Route: Capsule and Tablet; Oral
Zejula
Niraparib Tosylate
Applicant:
Glaxosmithkline LLC
| Patents | Expiration Date |
| US8071579 | 2027-08-12 |
| US8071579 | 2027-08-12 |
| US8143241 | 2027-08-12 |
| US8143241 | 2027-08-12 |
Ingredients: Niraparib Tosylate
Route: Capsule and Tablet; Oral
Zolinza
Vorinostat
Applicant:
Merck Sharp And Dohme LLC (A Sub Of Merck And Co Inc)
| Patents | Expiration Date |
| US7399787 | 2025-02-09 |
| US7851509 | 2024-02-21 |
| US8450372 | 2028-03-18 |
Ingredients: Vorinostat
Route: Capsule; Oral
Zydelig
Idelalisib
Applicant:
Gilead Sciences Inc
| Patents | Expiration Date |
| USRE44599 | 2025-07-21 |
Ingredients: Idelalisib
Route: Tablet; Oral
Zykadia
Ceritinib
Applicant:
Novartis Pharmaceuticals Corp
| Patents | Expiration Date |
| US8377921 | 2027-11-20 |
| US8377921 | 2027-11-20 |
Ingredients: Ceritinib
Route: Capsule and Tablet; Oral
Zytiga
Abiraterone Acetate
Applicant:
Janssen Biotech Inc
| Patents | Expiration Date |
| US8822438 | 2027-08-24 |
| US8822438 | 2027-08-24 |
Ingredients: Abiraterone Acetate
Route: Tablet; Oral
Conclusion
As a drug patent expires, it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand using Pharsight can not only help evaluate business opportunities but also help in refining market entry strategies.
However, there still lie legal and technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
The most recent example is the antitrust lawsuit against Natco Pharma and other generic drug manufacturers regarding the anti-cancer treatment medication Pomalidomide. Although the case was dismissed, the company’s shares fell significantly, causing a considerable negative impact on the company. Therefore, if proper research and threat analysis were conducted, developing a generic version of the medication wouldn’t be as daunting.
How to go about it?
Well, let’s start with getting in touch.
Authored by: Annie Sharma, Editorial Team
Insights by: Nikhil Kaushal, Product Development Team
